Cell therapy

#Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug discovery #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Oncology #Screening #Therapeutics

DDW summer issue now out

2 July 2020 From the race to the COVID-19 cure to the new manufacturing technologies that could be a game changer for stem cell therapies. With COVID-19 still a significant feature in the drug discovery landscape, this issue looks at the race to finding a cure – from… Read More

#News

#Biologics / Biotechnology #Cell therapy #Clinical specialities #Clinical trials #Drug discovery #Gene therapy #Imaging #Lead discovery #Precision medicine #RNA

Clinical trial examines alpha-1-antitrypsin for severe COVID-19 infection

Clinician scientists at RCSI University of Medicine and Health Sciences, Ireland, have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care. In a paper published in the American Journal of Respiratory and Critical Care Medicine, the team, led by RCSI Professors… Read More

#Covid-19 #News

#Cell therapy #Gene editing #Gene therapy #High Content Screening #Stem cells

New paper published on gene editing technique in hematopoietic stem cells

30 June 2020 Image: National Cancer Institute The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire have published data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology. The paper, entitled Efficient gene editing of… Read More

#News

#Cell therapy #Drug development #Gene therapy #Toxicology

PARP inhibitor could be effective treatment for childhood neuroblastoma

29 June 2020 Image: National Cancer Institute A type of drug already used to treat breast and ovarian cancer, called a PARP inhibitor, may be useful in treating children with high-risk neuroblastoma, a childhood tumour with a low survival rate, a new study suggests. Neuroblastoma is a cancer… Read More

#News

#Academic #Business #Cell therapy #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Leukaemia treatment mystery solved

26 June 2020 Image: National Cancer Institute A research team led by the University of Kent and Goethe-University Frankfurt am Main, has solved an almost 40-year old mystery in leukaemia therapy and the drug nelarabine. Acute lymphoblastic leukaemia (ALL) is the most common cancer in children. Read More

#News

#Biomarkers #Business #Cell therapy #Gene therapy

Stephen Gunstream new Teknova CEO

25 June 2020 Teknova has appointed Stephen Gunstream as chief executive officer. Gunstream has nearly 20 years of experience in the life sciences industry, including positions as Vice President and General Manager for the research and clinical business at BD Biosciences and Chief Commercial Officer at Integrated DNA Technologies. Read More

#News

#AI / data analytics / healthtech / informatics #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Lead discovery #Lead optimisation #Regulatory #Target validation

Avacta positive on evaluation of COVID-19 test strips

Avacta Group has announced that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been developed and evaluated by partners at Cytiva (formerly GE Healthcare Life Sciences) and show positive initial performance data. In mid-May Avacta provided Affimer reagents that are specific to the SARS-COV-2… Read More

#Covid-19 #News

#Business #Cell therapy #Clinical trials #Drug development #Oncology #Preclinical #Stem cells

Scenic Biotech awarded fund to progress immuno-oncology program

23 June 2020 Image: Austin Distel The Innovation Credit is awarded by the Dutch government through its agency RVO of the Ministry of Economic Affairs and Climate Policy and is aimed at the development of promising and challenging innovations. The €3.1million fund will support the preclinical… Read More

#News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Microbiology #RNA #Stem cells #System biology

Taconic Biosciences to distribute critical COVID-19 mouse model

Taconic Biosciences has announced an exclusive agreement with the University of Texas Medical Branch at Galveston (UTMB) to distribute humanised ACE2 mice for coronavirus research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells, causing infection. Due to differences between the mouse and human… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Business #Cell therapy #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Regulatory #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

CatalYm to present data on immunotherapy of cancer at AACR Annual Meeting

19 June 2020 CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June. Tumor-derived GDF-15 suppresses T-lymphocyte recruitment… Read More

#News

#Biologics / Biotechnology #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Stem cells

Avacta collaboration offers update on Affimer therapy for COVID-19

Avacta Group, in collaboration with the Centre for Virus Research at the University of Glasgow, has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein, prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection. Avacta… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology / Virology & Vaccines #RNA

Cobra Biologics signs manufacture agreement with AstraZeneca for COVID-19 vaccine candidate

Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based… Read More

#Covid-19 #News

#Analysis #Biochemistry #Cell therapy #Clinical trials #Gene therapy #Oncology

AstraZeneca presents results from Calquence (acalabrutinib) trials

16 June, 2020 The global science-led biopharmaceutical company said the detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult… Read More

#News

#Cell therapy #Gene therapy

Kite receives approval for CAR T cell therapy manufacturing in Europe

15 June, 2020 Kite, which is part of research-based biopharmaceutical company Gilead Sciences, announced it has received approval to implement a variation to the Yescarta (axicabtagene ciloleucel) Marketing Authorisation from the European Medicines Agency (EMA) for end-to-end manufacturing at its facility located in Amsterdam, The Netherlands. With this… Read More

#News

#Business #Cell therapy #Clinical trials #Gene therapy #Immunology / Virology & Vaccines

Oxford Biomedica agreement with Vaccines Manufacturing and Innovation Centre

8 June, 2020 The UK based gene and cell therapy group announced that it has signed a collaboration agreement on June 8 with the Vaccines Manufacturing and Innovation Centre (VMIC) to provide the UK’s first strategic vaccine development and advanced manufacturing capability. According to Oxford Biomedica, the five-year… Read More

#News

#Cell therapy #Oncology

Faron presents Part I of the Matins trial safety and efficacy results

01 June, 2020 The clinical stage biopharmaceutical company presented the safety and efficacy results from Part I of the Matins trial in a poster at the virtual ASCO20 (American Society of Clinical Oncology) Annual Meeting. During the ASCO poster presentation, Faron Pharmaceuticals said the ongoing phase I/II Matins… Read More

#News